Eikelboom, John W.

Dabigatran versus warfarin in patients with atrial fibrillation

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 11,215

Apixaban in patients with atrial fibrillation

Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 2,483

Rivaroxaban with or without aspirin in stable cardiovascular disease

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 2,438

Colchicine in Patients with Chronic Coronary Disease

Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine

Acute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

Cited by 2,299

Idarucizumab for Dabigatran Reversal

Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis Mechanisms

Cited by 1,552

Dabigatran versus warfarin in patients with mechanical heart valves

Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and Treatments

Cited by 1,506

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 1,081

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 870

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism

Brighton, T. A., Eikelboom, J. W., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., et al. (2012) · New England Journal of Medicine

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 563

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet

Atrial Fibrillation Management and OutcomesInflammatory Biomarkers in Disease Prognosis

Cited by 490

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Dans, A. L., Connolly, S. J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., Ezekowitz, M., Oldgren, J., Eikelboom, J. W., Reilly, P. A., et al. (2013) · Circulation

Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular Diseases

Cited by 484

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

Anand, S. S., Caron, F., Eikelboom, J. W., Bosch, J., Dyal, L., Aboyans, V., Abola, M. T., Branch, K. R. H., Keltai, K., Bhatt, D. L., et al. (2018) · Journal of the American College of Cardiology

Peripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular Diseases

Cited by 466

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., et al. (2014) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 396

Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study

Marijon, E., Le Heuzey, J.-Y., Connolly, S., Yang, S., Pogue, J., Brueckmann, M., Eikelboom, J., Themeles, E., Ezekowitz, M., Wallentin, L., et al. (2013) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 314

Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES

Vanassche, T., Lauw, M. N., Eikelboom, J. W., Healey, J. S., Hart, R. G., Alings, M., Avezum, A., Diaz, R., Hohnloser, S. H., Lewis, B. S., et al. (2015) · European Heart Journal

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 313

Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration

Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 262

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial

Diener, H.-C., Eikelboom, J., Connolly, S. J., Joyner, C. D., Hart, R. G., Lip, G. Y., O'Donnell, M., Hohnloser, S. H., Hankey, G. J., Shestakovska, O., et al. (2012) · The Lancet Neurology

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 177

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 158

Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial

Flaker, G. C., Eikelboom, J. W., Shestakovska, O., Connolly, S. J., Kaatz, S., Budaj, A., Husted, S., Yusuf, S., Lip, G. Y. H., & Hart, R. G. (2012) · Stroke

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 94

Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis

Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 90

The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

Gommans, J., Yi, Q., Eikelboom, J. W., Hankey, G. J., Chen, C., & Rodgers, H. (2013) · BMC Geriatrics

Folate and B Vitamins ResearchBone health and osteoporosis research

Cited by 42

Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant

Thom, J., Ivey, L., & Eikelboom, J. (2003) · Journal of Thrombosis and Haemostasis

Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis Mechanisms

Cited by 38